Search filters

List of works by Cyril H. Benes

A coding single-nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors

scientific article

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

scientific article published on 25 September 2018

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer

scientific article published on 25 September 2018

HER2 expression identifies dynamic functional states within circulating breast cancer cells

scientific article published on 24 August 2016

KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition

scientific article published on 16 October 2018

Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis

scientific article published on 6 January 2015

MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

scientific article published on 21 February 2020

NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263

scientific article published on 17 September 2018

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

scientific article published on 08 October 2019

Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features

scientific article published on 01 June 2019

Systematic identification of genomic markers of drug sensitivity in cancer cells

scientific article (publication date: 28 March 2012)

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma

scientific article published on 20 May 2019

Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma

scientific article published on 01 May 2018

The Ewing family of tumors rely on BCL-2 and BCL-X to escape PARP inhibitor toxicity

article

Paulina is supported by:

About Paulina

Help